Patent classifications
A23L29/03
FOOD PRODUCT AMENDMENT APPARATUS AND METHOD OF USE THEREOF
The invention comprises an apparatus and a method for amending an incomplete product and/or a product to form an amended product, such as by receiving the original product in a first pressurized container, breaking a pressure seal of the first pressurized container, adding tetrahydrocannabinol (THC) to the first pressurized container, and resealing the first pressurized container, such as where optionally a portion of the amendment process is at a second physical location separated from a first location by a state line and/or a legislative boundary.
FOOD PRODUCT INJECTOR AMENDMENT APPARATUS AND METHOD OF USE THEREOF
The invention comprises an apparatus and a method for amending a food product, comprising the steps of: (1) receiving into a second geographic zone the food product from a first geographic zone, where packaging greater than five milligrams per serving of tetrahydrocannabinol in the food product is: (a) illegal in the first geographic zone and (b) legal in the second geographic zone; (2) forming a composition of the tetrahydrocannabinol comprising a viscosity of less than 2,000 mPa.Math.sec; (3) injecting the food product with the composition of tetrahydrocannabinol to form an amended food product; and optionally (4) forming an emulsion of the tetrahydrocannabinol, an emulsifier, and water, the emulsion comprising, excluding particle sizes of less than 20 nm, a mean particle size of less than 1000 nm and a viscosity of less than 100 mPa.Math.sec.
Organosilicon compound microparticles and process for their preparation
Organosilicon compound microparticles and process for their preparation It is provided a combination of an organosilicon compound and arabic gum in the form of microparticles, wherein the organo silicon has the formula (I): wherein R.sup.1 and R.sup.2 are independently selected from hydrogen and a (C.sub.rC.sub.4)alkyl group; R.sup.3 is hydroxyl; and R.sup.4 is hydroxyl or a (C.sub.rC.sub.4) alkyl group; the arabic gum is forming a polymeric matrix having interspaces, and the organosilicon compound is distributed in the interspaces of the polymeric matrix. It is also provided a process for its preparation and a composition comprising the mentioned combination.
CANNABINOID EMULSIONS
This technology described in this specification pertain to emulsions comprising a continuous aqueous phase, a disperse oil phase comprising a cannabinoid, and an emulsifier comprising quillaja saponin, wherein said disperse oil phase has a median particle size (d50) of 200 nm or less, and wherein the weight fraction of the disperse oil phase in the emulsion is at least 35 wt. % based on the weight of the emulsion; and/or the weight ratio of water to disperse oil phase in the emulsion is less than 1.15:1.0.
CLEAR PLANT EXTRACT EMULSION AND METHOD FOR PREPARATION
A method for preparing a clear plant extract emulsion is provided. Sugar is mixed with water. A bitter blocker is added to the mixed sugar and water to form an aqueous phase. The aqueous phase is combined with an oil phase including a plant extract and sucrose ester. The combined aqueous phase and oil phase are mixed under heat. A two-part homogenization of the combined aqueous and oil phases is performed resulting in a clear emulsion concentrate with a low turbidity.
Methods of making and using polyphenols complexed with a protein, peptide, amino acid, polysaccaride, disaccharide, or monosaccharide
The present invention a polyphenol complexes with amino acids, peptides, proteins, glycosaminoglycans, polysaccharides, mucopolysaccharide, disaccharides, monosaccharides, amino sugars, glycol-proteins, DNA/RNA oligonucleotides, mRNA, siRNA, antibodiesor other micro- or macro biomolecules.
Hydrocarbon oil for a therapeutic use
A hydrocarbon oil intended to be used as a drug including a content by weight of isoparaffins ranging from 90 to 100%, a content by weight of normal paraffins ranging from 0 to 10% and having a content of carbon of biological origin greater than or equal to 90% relative to the total weight of the hydrocarbon oil.
NON-RACEMIC BETA-HYDROXYBUTYRATE COMPOUNDS AND COMPOSITIONS ENRICHED WITH THE R-ENANTIOMER AND METHODS OF USE
Ketogenic compositions include a non-racemic mixture of beta-hydroxybutyrate salts and acid(s) enriched with the R-enantiomer. The compositions are enriched with the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved yet contains an amount of the S-enantiomer to provide alternative benefits. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for increasing ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate contains from about 50.5% to 99.5% by enantiomeric equivalents of R-beta-hydroxybutyrate and from about 49.5% to about 0.5% by enantiomeric equivalents of S-beta-hydroxybutyrate.
NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR
The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases or tumors, containing, as an active ingredient, a tricyclic compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and a health food composition for preventing or alleviating autoimmune diseases or tumors, containing the tricyclic compound as an active ingredient,
##STR00001##
wherein the tricyclic compound represented by Chemical Formula 1 has an excellent inhibitory activity against IRAK4, and thus can be usefully used for the prevention, treatment, or alleviation of autoimmune diseases or tumors.
Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
In various implementations, beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to cause weight loss, weight maintenance, elevate blood ketone levels, maintain blood ketone levels, reduce blood glucose levels, maintain blood glucose levels, improve energy, focus, mood, cognitive function, or aide with neurological or inflammatory disorders and/or combinations thereof. Other compounds may include short chain fatty acids, short chain triglycerides, medium chain fatty acids, medium chain triglycerides, long chain fatty acids, long chain triglycerides, berberine, metabolites of berberine (e.g., dihydroberberine), and/or combinations thereof.